Abstract
The emergence of a new coronavirus presents a huge risk to public health worldwide and has spread widely amongst the human population. Since its emergence, the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is frequently evolving by mutation and genetic recombination to give rise to new viral variants. These emerging variants pose a challenge to existing COVID-19 management strategies and vaccine efficacy. Interruption of viral spread is required as the merging variants pose higher transmissibility than the previous ones. To achieve this, local protection of the respiratory tract with immunity is essential. Here, we advocate the use of pulmonary/inhalable vaccines to achieve this goal.
| Original language | English |
|---|---|
| Article number | 1309 |
| Number of pages | 5 |
| Journal | Vaccines |
| Volume | 10 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 13 Aug 2022 |
Keywords
- Vaccine
- Mucosal immunity
- IGA
- Intranasal Vaccine
- Inhalable Vaccine
- Covid-19
- Sars-cov-2
- Pulmonary Vaccine
Access to Document
- Inhalable vaccines: can they help control pandemics?
Copyright 2022 The Authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.